A Phase Ib Multi-center, Open-label, 4-arm Dose-escalation Study of Oral BEZ235 and BKM120 in Combination With Weekly Paclitaxel in Patients With Advanced Solid Tumors and Weekly Paclitaxel/Trastuzumab in Patients With HER2+ Metastatic Breast Cancer.
Phase of Trial: Phase I
Latest Information Update: 16 Feb 2017
At a glance
- Drugs Buparlisib (Primary) ; Dactolisib (Primary) ; Paclitaxel; Trastuzumab
- Indications Advanced breast cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Novartis
- 15 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Oct 2014 Planned End Date changed from 1 May 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
- 15 Jan 2014 Planned End Date changed from 1 Dec 2013 to 1 May 2014 as reported by ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History